Triple
T21057571
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | fingolimod |
E518759
|
entity |
| Predicate | targetsReceptor |
P142668
|
FINISHED |
| Object | S1P5 receptor |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: S1P5 receptor | Statement: [fingolimod, targetsReceptor, S1P5 receptor]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: S1P5 receptor Context triple: [fingolimod, targetsReceptor, S1P5 receptor]
-
A.
S1P4 receptor
The S1P4 receptor is a G protein–coupled sphingosine-1-phosphate receptor primarily expressed in immune cells, where it regulates immune cell trafficking and function.
-
B.
S1P3 receptor
The S1P3 receptor is a G protein–coupled sphingosine-1-phosphate receptor involved in regulating vascular tone, immune cell trafficking, and cardiovascular function.
-
C.
CB2 receptor
The CB2 receptor is a cannabinoid receptor primarily expressed in immune and peripheral tissues, where it modulates inflammation and immune responses and serves as a key target of compounds like THC.
-
D.
CB1 receptor
The CB1 receptor is a G protein–coupled cannabinoid receptor in the brain and nervous system that mediates most of the psychoactive effects of cannabis.
-
E.
CCR5
CCR5 is a human cell-surface chemokine receptor best known as a key co-receptor for HIV entry into immune cells and as a target for both natural resistance and gene-editing interventions against HIV infection.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: S1P5 receptor Target entity description: The S1P5 receptor is a G protein–coupled sphingosine-1-phosphate receptor subtype primarily expressed in the central nervous system and immune cells, where it regulates cell migration, survival, and vascular integrity.
-
A.
S1P4 receptor
The S1P4 receptor is a G protein–coupled sphingosine-1-phosphate receptor primarily expressed in immune cells, where it regulates immune cell trafficking and function.
-
B.
S1P3 receptor
The S1P3 receptor is a G protein–coupled sphingosine-1-phosphate receptor involved in regulating vascular tone, immune cell trafficking, and cardiovascular function.
-
C.
CB2 receptor
The CB2 receptor is a cannabinoid receptor primarily expressed in immune and peripheral tissues, where it modulates inflammation and immune responses and serves as a key target of compounds like THC.
-
D.
CB1 receptor
The CB1 receptor is a G protein–coupled cannabinoid receptor in the brain and nervous system that mediates most of the psychoactive effects of cannabis.
-
E.
CCR5
CCR5 is a human cell-surface chemokine receptor best known as a key co-receptor for HIV entry into immune cells and as a target for both natural resistance and gene-editing interventions against HIV infection.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b5053ac48190921529544959e906 |
completed | April 16, 2026, 10:08 a.m. |
| NER | Named-entity recognition | batch_69e6fd81434c8190aedfddf937f82322 |
completed | April 21, 2026, 4:30 a.m. |
Created at: April 16, 2026, 2:37 p.m.